Medivir AB
The answer first
Does Medivir beat the market?
Yes, Medivir has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 25% of Nordic stocks
- Quality76
- Value8
- Trend34
No. 117 of 195 in healthcare
Max for seven days
Follow Medivir with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Medivir
Your first answer is free, no account needed.
Do you own Medivir, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Medivir and a few more. Free, no card.
Super Stock+44.6%In short
- Medivir has risen 150.3% over the past year, including dividends.
- Overall, Medivir ranks better than 25% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 95.7%. The price is 99.3% below its peak now.
What do analysts think of Medivir?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 25% of Nordic stocks.
No. 117 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 68 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.03
- Asset turnoverSales divided by everything the company owns0.03
- Return on equityProfit divided by equity−30.6%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 147 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.3
- P/SPrice divided by sales79.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 99 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−42.6%
- 6 months−45.6%
- 9 months−19.3%
- 12 months+150.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Medivir
6 funds we follow own Medivir. The share is how much of the fund the stock makes up.
- Sweden6
From the funds' latest known holdings.
About Medivir
Medivir AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C.


See the full analysis of Medivir.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card